Vaccinia and other poxvirus expression vectors.
Over the past year improvements have been made in recombinant vaccinia virus gene expression and a new method for inserting DNA into the poxvirus genome has been developed, along with alternative methods for selecting recombinant viruses. Attenuated and non-replicating vaccinia virus and avian poxvirus vectors are now being used successfully. Field trials of an oral, wild-life rabies vaccine and phase 1 testing of human vaccines derived from vaccinia virus are underway.
Moss
B
B
Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, MD 20892.
D000818:Animals; D001709:Biotechnology; D015870:Gene Expression; D005818:Genetic Engineering; D005822:Genetic Vectors; D011212:Poxviridae / Q000235:genetics*; D014614:Vaccines, Synthetic / Q000302:isolation & purification; D014616:Vaccinia virus / Q000235:genetics* / Q000276:immunology; D014765:Viral Vaccines / Q000302:isolation & purification
D014614:Vaccines, Synthetic; D014765:Viral Vaccines